Powered By
ESTROGEN RECEPTOR ANTAGONIST
Orserdu (elacestrant) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat postmenopausal women and adult men with certain kinds of breast cancer.
These insights are based on 77 comments about Orserdu from MyBCTeam members. These are the experiences of a small number of individuals and are not meant to be medical advice.
Benefits:
Considerations:
Orserdu is a type of estrogen receptor blocker. It attaches to estrogen receptor-alpha and helps break down this receptor in cancer cells. In ER-positive, HER2-negative breast cancer, this can slow estrogen-driven cancer cell growth.
Doctors prescribe Orserdu when certain adults have ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. Metastatic breast cancer means the cancer has spread to other parts of the body. Orserdu is used after the cancer has gotten worse following at least one endocrine therapy.
Orserdu is given as a tablet taken by mouth, usually once a day at about the same time each day. It should be taken with food and swallowed whole.
Treatment usually continues until the cancer gets worse or side effects become unacceptable or intolerable.
The recommended dose of Orserdu for breast cancer is 345 milligrams taken by mouth once daily with food. Doses should be taken around the same time each day.
Doctors may pause treatment, lower the dose, or stop treatment if side effects are serious or too hard to manage.
This information is based on the prescribing information, but your healthcare provider may tailor your treatment plan. Always follow their guidance.
These insights are based on 77 comments about Orserdu from MyBCTeam members.
Members who use Orserdu often say it helps to stay in close contact with your oncology team, especially when side effects or scan results change. They also commonly mention taking it with food, keeping up with blood work and scans, and giving the treatment some time to see how it is working.
Take Orserdu with food to help reduce nausea and vomiting.
“Always remember to eat something before taking it. Other than a little fatigue and minor bone pain, it’s been so much easier on my body than the previous chemo I was taking!”
Track appetite changes, diarrhea, and fevers when side effects pick up.
“I’m beginning to experience more side effects from the Orserdu now. Chills and sweats but no fever, diarrhea, no appetite.”
Give scans and tumor markers time to show whether treatment is helping.
“I just started a targeted therapy called Orserdu three months ago. I just had my PET scan, and I’m having a good response. Some shrinkage of tumors, so we’re heading in the right direction.”
Connect with others who understand life with breast cancer. Join MyBCTeam for free.
In clinical trials of Orserdu used alone for postmenopausal women and adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after disease progression following at least one line of endocrine therapy, the most common side effects were those reported in more than 10 percent of people taking Orserdu.
These side effects include:
Orserdu can cause serious side effects that may require immediate medical attention. These include:
Get medical help right away if you think you are having a serious reaction.
Stemline Therapeutics, the manufacturer of Orserdu, offers the Orserdu Co-Pay Card Program. Eligible people with commercial insurance may pay as little as $0 for their medication with this card.
The Orserdu Co-Pay Card Program is available through Stemline ARC, which offers support and may help with paying for your medicine. The program is not available to people enrolled in Medicare, Medicaid, TRICARE, or another federal or state healthcare program.
To learn more, visit the Orserdu Co-Pay Card Program or call 800-519-2140.
Before starting Orserdu, your doctor will test for ESR1 mutations in a plasma sample and verify pregnancy status if you can become pregnant.
Tell your doctor about all medications you take, including prescription drugs, over-the-counter medicines, and supplements.
If you miss a dose by more than six hours, skip it and take your next dose the following day at your regular time. If you vomit after taking a dose, do not take another dose that day. Take your next dose the following day at your regular time.
Orserdu can harm your baby if you are pregnant. Females who can become pregnant should use effective birth control during treatment and for one week after the last dose. Males with female partners who can become pregnant should use effective birth control during treatment and for one week after the last dose.
Orserdu may affect fertility in males and females. Do not breastfeed during treatment with Orserdu and for one week after the last dose.
These answers are fact-checked by our editorial staff.
How effective is Orserdu?
In a study of people with ER-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations, median progression-free survival was 3.8 months with Orserdu. It was 1.9 months with fulvestrant or an aromatase inhibitor. Progression-free survival means the time people lived without their cancer getting worse or dying.
Overall survival was not significantly different between the groups in this study.
What tests or monitoring are needed with Orserdu for breast cancer?
Lipid levels should be checked before starting and periodically during treatment with Orserdu because increased cholesterol and triglycerides may occur. Your healthcare provider may also monitor lab tests because increased liver tests, decreased sodium, increased creatinine, and decreased hemoglobin were reported.
On MyBCTeam, people share their experiences with breast cancer, get advice, and find support from others who understand.
Learn more about Orserdu and breast cancer care:
More resources from MyBCTeam that mention Orserdu
Become a member to get even more
Join
Your Privacy Choices
